Autolus Therapeutics plc (AUTL)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$1.86−$0.0550 (−2.88%) on the dayAs of the close; data may be delayed.
AUTL price, last 12 months
Key stats
- Previous close
- $1.91
- Open
- $1.91
- Day range
- $1.85 – $1.95
- 52-week range
- $1.18 – $2.58
- Volume
- 1.4M
- Avg volume (20 days)
- 1.6M
- Market cap
- $493.7M
Performance
1W−4.4%
1M−20.4%
3M+15.2%
6M+43.8%
YTD−6.8%
1Y+18.9%
vs S&P 500, 1Y+2.1 pts
Technicals and fundamentals
About Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $493.7M